TheraFlu powder for oral solution with lemon flavour

País: Armenia

Idioma: inglés

Fuente: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Ingredientes activos:

paracetamol, pheniramine (pheniramine maleate), phenylephrine (phenylephrine hydrochloride), ascorbic acid

Disponible desde:

Delpharm Orleans

Código ATC:

N02BE51

Designación común internacional (DCI):

paracetamol, pheniramine (pheniramine maleate), phenylephrine (phenylephrine hydrochloride), ascorbic acid

Dosis:

325mg+ 20mg+ 10mg+ 50mg

formulario farmacéutico:

powder for oral solution with lemon flavour

Unidades en paquete:

(10) sachets 22,1g

tipo de receta:

OTC

Estado de Autorización:

Registered

Fecha de autorización:

2020-06-30

Ficha técnica

Property of GSK Consumer Healthcare SA
THERAFLU
Powder in Sachets
ACTIVES SUBSTANCES
Paracetamol 325mg; Phenylephrine hydrochloride 10mg; Pheniramine
maleate 20mg;
Ascorbic Acid 50mg
SUMMARY OF PRODUCT CHARACTERISTICS
Document status:
FINAL
Release date:
15 Apr 2020
Number of pages:
12
Property of GSK Consumer Healthcare SA
TABLE OF CONTENTS
1.
NAME OF THE MEDICINAL PRODUCT
.........................................................................
3
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
.............................................. 3
3.
PHARMACEUTICAL FORM
..............................................................................................
3
4.
CLINICAL PARTICULARS
.................................................................................................
3
4.1 THERAPEUTIC INDICATIONS
................................................................................................
3
4.2.
POSOLOGY AND METHOD OF ADMINISTRATION
................................................................... 3
4.3.
CONTRAINDICATIONS
.......................................................................................................
4
4.4.
SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE
.................................................... 4
4.5.
INTERACTIONS WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION ......... 5
4.6.
PREGNANCY AND LACTATION
.............................................................................................
6
4.7.
EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
............................................................ 6
4.8.
UNDESIRABLE EFFECTS
.......................................................................................................7
4.9.
OVERDOSE
.......................................................................................................................
8
5.
PHARMACOLOGICAL PROPERTIES
..............................................................................
10
5.1.
PHARMACODYNAMIC PROPERTIES
.........................................